

GENETRONICS BIOMEDICAL LTD

Form NT 10-Q

November 15, 2001

TABLE OF CONTENTS

PART I. REGISTRANT INFORMATION

PART II. RULE 12B-25(b) and (c)

PART III. NARRATIVE

PART IV. OTHER INFORMATION

SIGNATURE

Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 12B-25

NOTIFICATION OF LATE FILING

Form 10-K Form 20-F Form 11-K Form 10-Q

Form N-SAR

For Period Ended: September 30, 2001

Transition Report on Form 10-K Transition Report on Form 10-Q

Transition Report on Form 20-F Transition Report on

Form N-SAR Transition Report on Form 11-K

For the Transition Period Ended:

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

PART I. REGISTRANT INFORMATION

Full name of registrant: Genetronics Biomedical Corporation

Former name if applicable Genetronics Biomedical Limited

Address of principal executive office 11199 Sorrento Valley Rd.
San Diego, CA 92121-1334

PART II. RULE 12B-25(b) and (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check where appropriate.)

(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without reasonable effort or expense;

(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and

(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

Table of Contents

PART III. NARRATIVE

The Company needs additional time to file its 10-Q due to a recent corporate restructuring which impacted management and finance operations.

PART IV. OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification:

Markus Hofmann (858) 410-3108

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

Yes No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes No

If so; attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Genetronics Biomedical Corporation has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date November 14, 2001

By: /s/ William K. Dix

William K. Dix
Vice President Legal Affairs